

Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence

Sahay RK, et al. Cureus. 2020 Sep 28; 12(9):e10700.

- A retrospective, non-randomized, non-comparative, multi-centric real-world study included 4,858 type 2 diabetes mellitus (T2DM) patients (mean age of 52.67 years) taking glimepiride and metformin fixed-dose combinations (FDCs).
- Prescription analysis showed that glimepiride and metformin FDCs were the preferred choice for the management of diabetes across all the age groups. Further, glimepiride and metformin FDCs are suitable for early as well as long-standing diabetes.
- Among the available strengths, glimepiride 2 mg + metformin 500 mg combination were most widely prescribed, followed by glimepiride 1 mg + metformin 500 mg.

The real-world evidence in the Indian clinical setting indicates that glimepiride and metformin FDCs are widely used in the management of T2DM patients with comorbidities like hypertension, dyslipidemia, and diabetes complications.